|
TWST: We would like to begin with a brief historical sketch of Global Med and a
picture of the things you are doing at the present time.
Dr. Ruxin: Global Med Technologies is an e-health, medical information
technology company specializing in software for blood banks and hospitals. The
company is in a very exciting position today. Firstly, Global Med is one of the
leaders in its field. We have no debt and we have several million dollars in the
bank. We are cash flow positive and profitable, and we have great channel
partners like McKesson, GE Medical, and Siemens. Consequently, our products are
in some of the top institutions around the country, such as the Mayo Clinic,
Stanford, UCLA, National City of Hope, Memorial Sloan-Kettering, New York
Presbyterian, plus over 200 others. We are in a great position to leverage our
business model into substantial growth. TWST: What are the products and how do they work?
Dr. Ruxin: Our products manage and track blood. One needs to look at a blood
donor center as a manufacturing plant. The donor center takes in raw material,
which is obviously the blood, and then manufactures 15 to 20 new products:
packed cells, fresh frozen plasma, whole blood, factors, platelets, etc., and
all of these various products must be managed and tracked. On the hospital side
in the transfusion area, we link and interface our software with the transfusion
product, so we are Vein-to-Vein. From the time the product is donated at the
donor center to the time it is transfused at the hospital, our software manages
and tracks the entire process, which is governed by the FDA. Our product is a
Class 2 medical device and we have to have FDA clearance on the product, which
we have.
Tickers included in this excerpt: GLOB
For more information call (212) 952 7433. The
Wall Street Transcript does not endorse any of the comments made by interviewees, and does
not make stock recommendations.
|
|
